Skip to main content Skip to search Skip to main navigation

EMA: Updated Q&As for Biological Medicinal Products

EMA’s Biologics Working Party has updated the question-and-answer document for biological medicinal products, adding information on nitrogen gas for backfilling, container closure systems and prior knowledge.

The new advice includes:

  • Where nitrogen is used for backfilling (headspace gas), it should be included in the finished product composition as a footnote.
  • The suppliers of of container closure systems for the sterile finished product(e.g. rubber stoppers and glass cartridges) should be named in the common technical document (CTD 3.2.P.7).
  • Justifications based on prior knowledge should be included in the sections of the dossier where the product-specific data it is complementing or replacing would have been included.

The question on investigation of Low Endotoxin Recovery (LER) has been revised:
The updated response provides information on how to perform the studies, an adequate mitigation strategy, the handling of quality control samples, and the need to focus on the finished product.


Source:

EMA: Questions and answers for biological medicinal products


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

What are the Phases of a Working Cycle During a Steam Sterilisation Process?

What are the Phases of a Working Cycle During a Steam Sterilisation Process?

Here's the answer:
Read more
Damage Control: Complaints and Recalls

Damage Control: Complaints and Recalls

Complaint handling and product recalls are important components of the Pharmaceutical Quality System (PQS). They serve to identify defective medicinal products and ensure that appropriate measures are taken to protect patient safety, as required by law and the competent supervisory authority.

Read more
EMA: 9 New Nitrosamines for Appendix 1

EMA: 9 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

The European Medicines Agency (EMA) published an update to its “Quality of Medicines: Questions and Answers – Part 2”. The revision concerns the section on “Reduced testing of incoming starting materials”.
Read more
What Types of Impurities may be Present in Active Substances?

What Types of Impurities may be Present in Active Substances?


Read more
There’s Something in the Air – Cleanroom Technology in the Pharmaceutical Industry

There’s Something in the Air – Cleanroom Technology in the Pharmaceutical Industry

In pharmaceutical manufacturing, clean air is not a subjective perception but a precisely controlled technical condition that is essential for product safety. Heating, ventilation and air-conditioning (HVAC) systems ensure, through airflow management, air filtration and pressure control, that particles and microorganisms are kept away from critical areas. This is based on clearly defined requirements for air changes, cleanliness classes, airflow patterns and pressure concepts, all of which are designed according to the manufacturing process and contamination risk involved.
Read more
Previous
Next